Prostate Cancer - Results from #2000

Comparative analysis of robot-assisted and open approach for PSMA-radioguided surgery in recurrent prostate cancer. October 19, 2023

Patient and Context Factors in the Adoption of Active Surveillance for Low-Risk Prostate Cancer. October 19, 2023

Quantitative [68Ga]Ga-PSMA-11 PET biomarkers for the analysis of lesion-level progression in biochemically recurrent prostate cancer: a multicentre study. October 19, 2023

Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE). October 18, 2023

Radioligand Therapy With 177Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer: Oncological Outcomes and Toxicity Profile. October 18, 2023

Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study. October 18, 2023

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. October 18, 2023

Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer. October 18, 2023

RAGE as a Novel Biomarker for Prostate Cancer: A Systematic Review and Meta-Analysis. October 17, 2023

Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis. October 17, 2023

Cancer Detection Rate and Abnormal Interpretation Rate of Prostate MRI in Patients with Low-grade Cancer. October 17, 2023

Impact of Prostate Cancer Related Genitourinary Radiation Injury on Mental Health Diagnosis and Treatment: Assessment of 55,425 Men. October 17, 2023

Prostate cancer image guided radiotherapy: Why the commotion over rectal volume and motion? October 17, 2023

Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer. October 17, 2023

Concurrent targeting of HDAC and PI3K to overcome phenotypic heterogeneity of castration-resistant and neuroendocrine prostate cancers. October 16, 2023

Impact of operator expertise on transperineal free-hand mpMRI-fusion-targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicenter prospective learning curve. October 16, 2023

Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews. October 16, 2023

177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study). October 16, 2023

Population-based patient-reported quality of life outcomes following low-dose-rate versus high-dose-rate brachytherapy monotherapy for low-intermediate risk prostate cancer. October 16, 2023

Ethnic differences in prostate cancer presentation: a time for testing advocacy. October 13, 2023

Page 101 of 1439